AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Brendan Coffey, The Motley Fool
Sat, August 29, 2026 at 11:11 PM GMT+5:30
6 min read
Choosing between AbbVie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) requires balancing the potential for aggressive pharmaceutical growth against the stability of a diversified medical conglomerate
AbbVie is a focused biopharmaceutical player known for its dominance in immunology, whereas Johnson & Johnson operates a broader business model following its separation from its consumer health division. Investors often compare these two when looking for reliable dividends and exposure to the healthcare sector
The case for AbbVie
Within the landscape of pharmaceutical stocks, AbbVie focuses on discovering and commercializing treatments for serious conditions in immunology, oncology, and aesthetics. The company relies on three major wholesale distributors, McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR), which account for almost all of its U.S. sales. Customer concentration like this adds a layer of risk to the business because a disruption with any single partner could impact distribution.
In FY 2025, revenue reached nearly $61.2 billion, representing a growth of roughly 8.7% over the previous year. The company generated a net income of approximately $4.3 billion during this period. This resulted in a net margin of close to 7%, which measures the percentage of revenue remaining as profit after all expenses are paid
As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of -21x, indicating that its total liabilities exceed its shareholders’ equity. The so-called current ratio, which measures the ability to pay short-term debts with short-term assets, is approximately 0.7x. Despite these figures, the business generated more than $17.8 billion in free cash flow, which is the cash left over after the company pays for its operating costs and capital investments
The case for Johnson & Johnson
Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. Its largest product group, the Darzalex portfolio, accounted for approximately 15% of total revenues in 2025, providing a strong foundation for its pharmaceutical business. The company maintains a global reach, distributing its products directly to hospitals, wholesalers, and healthcare professionals in nearly every country
In FY 2025, revenue reached approximately $94.2 billion, which was an increase of nearly 6% compared to the prior year. The company reported a net income of close to $26.8 billion during this fiscal period, a significant increase from $14.1 billion the prior year. This led to a net margin of roughly 29%, indicating the high level of profit the business generates from every dollar of sales
